Combined VeDDRA list of clinical terms for reporting suspected adverse events in animals and humans to veterinary medicinal products
Pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2024
Poorly extractable and/or non- radiolabelled substances - Scientific guideline
Determining the fate of veterinary medicinal products in manure - Scientific guideline
Agenda - PDCO agenda of the 25-28 June 2024 meeting
Human medicines European public assessment report (EPAR): Pyzchiva, ustekinumab, Date of authorisation: 19/04/2024, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Rezolsta, darunavir,cobicistat, Date of authorisation: 19/11/2014, Revision: 17, Status: Authorised
Committee for Medicinal Products for Veterinary Use (CVMP): 18-20 June 2024, European Medicines Agency, Amsterdam, the Netherlands, from 18 June 2024 to 20 June 2024
Minutes of the CVMP meeting 18-19 June 2024
European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting, European Medicines Agency, Amsterdam, the Netherlands, from 2 July 2024 to 3 July 2024